How does Tirzepatide work?
Dual agonist hitting GLP-1 receptors (like Semaglutide) AND GIP receptors. The GIP arm adds an additional satiety and insulin-secretion lever, producing stronger weight loss than GLP-1 alone in head to head trials. In plain terms, Tirzepatide is strong weight loss with a cleaner side effect profile than semaglutide. A dual agonist (GLP-1 + GIP), FDA-approved as Mounjaro / Zepbound. Mechanistic detail like this comes largely from preclinical and early research, the human picture is limited.
What people use it for
- Users who couldn't tolerate semaglutide
- Metabolic-syndrome adults under provider guidance
- Long-term weight management
References
- Tirzepatide Once Weekly for Treatment of Obesity (SURMOUNT-1) — Jastreboff AM et al., NEJM, 2022
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — Frías et al., N Engl J Med, 2021
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial — Garvey et al., Lancet, 2023
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tirzepatide
Last updated 2026-06-06.